Thailand Food and Drug Administration (Thai FDA)
Thailand Food and Drug Administration (Thai FDA) is the structural Thai regulatory agency under the Ministry of Public Health responsible for pre-market approval and post-market surveillance of food, pharmaceuticals, cosmetics, medical devices, and controlled substances. Administers GMP/GLP certification for manufacturing facilities, product registration, clinical trial authorization, and import-export permits. Relevant to pharmaceutical market-entry, medical-device distribution, cosmetic-OEM exports, and cannabis/CBD product regulation. Coordinates with ASEAN Harmonization frameworks on mutual recognition of product standards. Enforcement actions impact supply-chain compliance for MNC and Thai-listed healthcare operators.
Snapshot
Headline numbers a buyer checks first.
Established
1974
founding
Originally part of MoPH; separated as independent department
Drug registration timeline
12-36 months
2024
12-24 months generics; 18-36 months innovator drugs
Reports to
Ministry of Public Health (MoPH)
2024
Regulated product categories
5
2024
Food, pharmaceuticals, cosmetics, medical devices, controlled substances
Profile overview
Thailand Food and Drug Administration (Thai FDA) is the structural Thai regulatory agency under the Ministry of Public Health responsible for pre-market approval and post-market surveillance of food, pharmaceuticals, cosmetics, medical devices, and controlled substances. Administers GMP/GLP certification for manufacturing facilities, product registration, clinical trial authorization, and import-export permits. Relevant to pharmaceutical market-entry, medical-device distribution, cosmetic-OEM exports, and cannabis/CBD product regulation. Coordinates with ASEAN Harmonization frameworks on mutual recognition of product standards. Enforcement actions impact supply-chain compliance for MNC and Thai-listed healthcare operators.
Programs administered
Pharmaceuticals
Drug registration, GMP certification
Administers pre-market drug registration for pharmaceutical products. GMP certification required for Thai manufacturing facilities. Maintains National List of Essential Medicines (NLEM) and coordinates compulsory licensing decisions with MOPH.
Food safety
Food approval, GMP food standards
Food product registration, food additive approval, and GMP compliance for food manufacturers. Novel food approval pathway (B.E. 2563/2020 Notification) relevant to alt-protein, functional food, CBD-food products.
Medical devices
Device registration, import permits
Medical device pre-market registration, import-export permit, and post-market surveillance. Class III/IV high-risk devices require pre-market approval; relevant to hospital procurement and MedTech market entry.
Cosmetics, controlled substances
Cosmetic notification, cannabis regulation
Cosmetic product notification system for OEM exports. Administered post-2022 cannabis decriminalisation regulations; subsequent re-classification from 2024 affecting CBD and cannabis derivatives.
Thai FDA regulatory scope vs peer ASEAN agencies
Regulatory authority comparison for pharmaceutical market entry
Thai FDA (TFDA)
Country
Thailand
Drug approval timeline
12-24 months (generic); 18-36 (innovator)
ASEAN harmonisation
ASEAN MRA member
BPOM
Country
Indonesia
Drug approval timeline
12-24 months
ASEAN harmonisation
ASEAN MRA member
NPRA
Country
Malaysia
Drug approval timeline
9-18 months (generic)
ASEAN harmonisation
ASEAN MRA member
HSA
Country
Singapore
Drug approval timeline
9-15 months (international)
ASEAN harmonisation
ASEAN MRA member
| Agency | Country | Drug approval timeline | ASEAN harmonisation |
|---|---|---|---|
| Thai FDA (TFDA) | Thailand | 12-24 months (generic); 18-36 (innovator) | ASEAN MRA member |
| BPOM | Indonesia | 12-24 months | ASEAN MRA member |
| NPRA | Malaysia | 9-18 months (generic) | ASEAN MRA member |
| HSA | Singapore | 9-15 months (international) | ASEAN MRA member |
Key drivers 2025-2026
Cannabis regulation
Post-2024 re-classification
Thailand's partial cannabis re-listing from 2024 affected CBD product rules. Thai FDA administers the regulatory boundary between medical cannabis, CBD-food, and controlled-substance classification.
ASEAN harmonisation
Mutual recognition agreements
ASEAN pharmaceutical harmonisation framework (PPWG) reduces duplicate registration requirements. Thai FDA MRA progress affects Thai pharmaceutical export competitiveness to ASEAN markets.
Novel foods
Alt-protein, lab-grown meat pathway
Thai FDA Novel Food approval pathway (B.E. 2563/2020) is the regulatory gatekeeping step for alt-protein, plant-based, and lab-grown meat products entering the Thai market or manufacturing for export.
Where this profile is featured
Reports that reference this entity in their operator concentration or analysis.
Featured in
The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway...
Regulatory framework including approval, essential-medicines list, compulsory-licensing.
Featured in
Thai Alt-Protein and Lab-Grown Meat: FDA Regulatory Pathway
Administers Novel Food approval pathway under B.E. 2563/2020 Notification.
Featured in
Thai Digital Health: Telemedicine, Doctor Raksa, and Hospital Adoption
Administers Novel Food approval pathway under B.E. 2563/2020 Notification.
Related Market profiles
Peers, parents, partners, agencies, and other Hospitals & Medical Tourism actors.
Competitor
Bumrungrad Hospital
Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.
Open Market profile →
Competitor
Bangkok Dusit Medical Services
Thailand's largest listed hospital group — 50+ hospitals across six brand families; > $3.19B FY2024 revenue.
Open Market profile →
Competitor
Bangkok Chain Hospital
Mid-market listed hospital operator — Kasemrad brand across 15+ hospitals; SSS, UCS contract-heavy franchise.
Open Market profile →
Sector peer
Asian Cosmetic Surgery Center
Bangkok cosmetic surgery center serving domestic and international patients.
Open Market profile →
Reports featuring this profile
The Thai Pharma Import Lane: Multinational Brands, Thai-FDA Pathway, and Generic Substitution
Regulatory framework including approval, essential-medicines list, compulsory-licensing.
Open report →
Sits alongside 5 other Atlas profilesThai Alt-Protein and Lab-Grown Meat: FDA Regulatory Pathway
Administers Novel Food approval pathway under B.E. 2563/2020 Notification.
Open report →
Sits alongside 5 other Atlas profilesThai Digital Health: Telemedicine, Doctor Raksa, and Hospital Adoption
Administers Novel Food approval pathway under B.E. 2563/2020 Notification.
Open report →
Sits alongside 5 other Atlas profilesRelated Market profiles
competitor
Bumrungrad Hospital
Thailand's medical-tourism flagship — first Asian hospital JCI-accredited (2002); >60% international-patient revenue mix.
competitor
Bangkok Dusit Medical Services
Thailand's largest listed hospital group — 50+ hospitals across six brand families; >THB 110B FY2024 revenue.
competitor
Bangkok Chain Hospital
Mid-market listed hospital operator — Kasemrad brand across 15+ hospitals; SSS, UCS contract-heavy franchise.